Back
Arcus Biosciences Quote, Financials, Valuation and Earnings

New Year, New Trades, Try A.I. Today
Learn to forecast trends with up to 87.4% proven accuracy -> Register Here
Sell
29
RCUS
Arcus Biosciences
Last Price:
20.47
Seasonality Move:
48.55%
7 Day Trial
ALL ACCESS PASS
$
7

Your Chance To Invest In The Green Energy Revolution!
Don't miss this one - click for more info and ADD THIS COMPANY TO YOUR WATCHLIST!Arcus Biosciences Price Quote
$20.47
-0.04 (-3.26%)
(Updated: February 4, 2023 at 4:28 AM ET)
Arcus Biosciences Key Stats
Sell
29
Arcus Biosciences (RCUS)
is a Sell
Day range:
$20.32 - $21.05
52-week range:
$16.74 - $39.75
Dividend yield:
0%
P/E ratio:
28.89
P/S ratio:
3.60
P/B ratio:
2.12%
Volume:
838.2K
Avg. volume:
1.2M
1-year change:
-29.95%
Market cap:
$1.5B
Revenue:
$382.9M
EPS:
$0.92
How Much Does Arcus Biosciences Make?
-
How Much Are Arcus Biosciences's Sales Annually?
RCUS Revenues are $382.9M -
How Much Profit Does Arcus Biosciences's Make A Year?
RCUS net income is $52.8M
Is Arcus Biosciences Growing As A Company?
-
What Is Arcus Biosciences's Growth Rate Quarterly?
Quarterly YoY revenue growth is 2.55% -
What Is Arcus Biosciences's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Arcus Biosciences Stock Price Performance
-
Did Arcus Biosciences Stock Go Up Last Month?
Arcus Biosciences share price went up by 1.53% last month -
Did RCUS's Share Price Rise Over The Last Year?
RCUS share price fell by -29.95% over the past 1 year
What Is Arcus Biosciences 52-Week High & Low?
-
What Is Arcus Biosciences’s 52-Week High Share Price?
Arcus Biosciences has traded as high as $39.75 over the past 52 weeks -
What Is Arcus Biosciences’s 52-Week Low Share Price?
Arcus Biosciences has traded as low as $16.74 over the past 52 weeks
Arcus Biosciences Price To Free Cash Flow
-
Is Arcus Biosciences Stock Overvalued?
Arcus Biosciences is trading at a price to free cash flow ratio of 3.66 -
Is Arcus Biosciences Stock Undervalued?
Arcus Biosciences EV to Free Cash Flow ratio is 1.01 -
What Is Arcus Biosciences’s Price Earnings Growth Ratio?
RCUS PEG ratio is 0.00 -
Is Arcus Biosciences Trading At A Premium To Earnings?
Arcus Biosciences EV to EBIT ratio is 5.11
Is It Risky To Buy Arcus Biosciences?
-
How Much Debt Does Arcus Biosciences Have?
Total long term debt quarterly is $0 -
How Much Cash Does Arcus Biosciences Have?
Cash and short term investments quarterly total is $1B -
What Is Arcus Biosciences’s Book Value Per Share?
Book value per share is 9.68
Is Arcus Biosciences Cash Flow Positive?
-
What Is RCUS Cash Flow From Operations?
Cash flow from operations (TTM) is $445.6M -
What Is Arcus Biosciences’s Cash Flow From Financing?
Cash flow from financing (TTM) is $33.5M -
What Is Arcus Biosciences’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$440.9M
Arcus Biosciences Return On Invested Capital
-
Is Management Doing A Good Job?
RCUS return on invested capital is 11.01% -
What Is Arcus Biosciences Return On Assets?
ROA measures how assets are converting to revenues and is 5.83% -
What Is RCUS Return On Equity?
ROE is a measure of profitability and is 11.01%
Arcus Biosciences Earnings Date & Stock Price
-
What Is Arcus Biosciences's Stock Price Today?
A single share of RCUS can be purchased today for 20.51 -
What Is Arcus Biosciences’s Stock Symbol?
Arcus Biosciences trades on the nyse under the ticker symbol: RCUS -
When Is Arcus Biosciences’s Next Earnings Date?
The next quarterly earnings date for Arcus Biosciences is scheduled on February 23, 2023 -
When Is RCUS's next ex-dividend date?
Arcus Biosciences's next ex-dividend date is February 6, 2023 -
How To Buy Arcus Biosciences Stock?
You can buy Arcus Biosciences shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Arcus Biosciences Competitors
-
Who Are Arcus Biosciences's Competitors?
Below is a list of companies who compete with Arcus Biosciences or are related in some way:
Arcus Biosciences Dividend Yield
Data Unavailable
Arcus Biosciences Analyst Estimates
YoY Growth | Past Surprise | |
---|---|---|
EPS: | 0% | 9.86% |
Revenue: | 254.94% | 51.56% |
Analyst Recommendations
Buy Recommendations: | 8 |
---|---|
Hold Recommendations: | 2 |
Sell Recommendations: | 0 |
Price Target: | 42.82 |
Upside from Last Price: | 108.77% |